Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Short Interest Update

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 2,490,000 shares, a drop of 22.7% from the February 13th total of 3,220,000 shares. Based on an average trading volume of 676,300 shares, the days-to-cover ratio is presently 3.7 days. Approximately 2.0% of the shares of the company are sold short.

Alnylam Pharmaceuticals Trading Up 4.7 %

ALNY stock opened at $253.11 on Tuesday. The firm has a fifty day moving average price of $255.57 and a 200 day moving average price of $259.72. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a market cap of $32.77 billion, a PE ratio of -116.64 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Jeffrey V. Poulton sold 967 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the sale, the chief financial officer now owns 32,786 shares of the company’s stock, valued at $8,366,003.62. This trade represents a 2.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $309,521.21. Following the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 in the last 90 days. 1.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Atria Investments Inc grew its holdings in shares of Alnylam Pharmaceuticals by 78.9% in the third quarter. Atria Investments Inc now owns 3,145 shares of the biopharmaceutical company’s stock valued at $865,000 after purchasing an additional 1,387 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Alnylam Pharmaceuticals by 55.3% in the 3rd quarter. GSA Capital Partners LLP now owns 2,860 shares of the biopharmaceutical company’s stock worth $787,000 after acquiring an additional 1,018 shares during the last quarter. Victory Capital Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 10.9% during the 3rd quarter. Victory Capital Management Inc. now owns 42,909 shares of the biopharmaceutical company’s stock worth $11,801,000 after purchasing an additional 4,229 shares during the period. Oppenheimer & Co. Inc. grew its holdings in Alnylam Pharmaceuticals by 11.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 1,906 shares of the biopharmaceutical company’s stock valued at $524,000 after purchasing an additional 190 shares during the last quarter. Finally, Huntington National Bank raised its position in Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ALNY has been the topic of several recent research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $310.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Morgan Stanley increased their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Sanford C. Bernstein decreased their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Finally, HC Wainwright raised their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.